Anna Rivkin, PHD

Anna Rivkin, PHD joined Foghorn as Chief Business Officer (CBO) in September 2024. She brings more than 20 years of expertise in a broad spectrum of complex business transactions, including establishing strategic alliances, R&D partnerships, in-licensing and M&A, across multiple disease areas.

Before joining Foghorn, Anna most recently held leadership roles at Bristol Myers Squibb (BMS) where she successfully oversaw strategic transactions across immunology, neuroscience, and cardiovascular disease as the Vice President of Business Development.

Dr. Rivkin has spearheaded transactions that are cumulatively valued at over $35 billion across a broad spectrum of deal types in multiple therapeutic areas. She brings a deep industry knowledge and a proven track record of leading teams to successfully navigate complex business transactions. As Vice President of business development at BMS, Anna helped evolve the BMS pipeline including leading high-impact deals such as the $14 billion purchase of Karuna Therapeutics and the $13 billion purchase of MyoKardia Therapeutics. Prior to BMS, Anna worked at Merck & Co., holding a number of roles of increasing responsibilities in business development and clinical research.

Anna received her Ph.D. in Neuroscience from Case Western Reserve University and holds a B.A. from Johns Hopkins University.